The plasma fractionation market in Europe is expected to grow from US$ 6,824.67 million in 2021 to US$ 10,402.95 million by 2028; it is estimated to grow at a CAGR of 6.2% from 2021 to 2028. Increasing geriatric population, increasing use of immunoglobulins in various therapeutic areas such as neurology, hematology, rare genetic disorders and autoimmune disorders along with growing demand for plasma derived therapies for management of diseases are all expected to boost plasma fractionation market in rest of Europe. Furthermore, various companies in Europe are investing more on research and development activities to develop and launch novel approaches in plasma therapies for management of diseases.
Europe Plasma Fractionation Market Overview
The Europe plasma fractionation market encompasses Germany, France, the UK, Spain, Italy, and the rest of Europe. The region holds a significant share in the global plasma fractionation market and is projected to grow at a robust rate in the coming years. Key drivers of this growth include an aging population, rising demand for immunoglobulins in treating chronic diseases, increasing prevalence of immune and bleeding disorders, and the expanding use of plasma-based therapies in disease management.
Impact of COVID-19 on Europe Plasma Fractionation Market Dynamics
The pandemic has reshaped medical practices across Europe, particularly in treating chronic conditions such as neurological, hematological, and respiratory diseases. With healthcare resources diverted toward critical COVID-19 care, the diagnosis and treatment of other illnesses have been affected. However, the crisis has also accelerated the adoption of plasma-based therapies. Several European regulatory bodies have endorsed convalescent plasma as a treatment for severe COVID-19 cases. For instance:
- France’s National Agency for Medicines and Health Products Safety (ANSM) approved immune plasma therapy for critically ill patients.
- The European Commission recommended emergency use of convalescent plasma in severe COVID-19 cases.
While these developments have provided a temporary boost to the Europe Plasma Fractionation Market, the broader shift in healthcare priorities has disrupted traditional treatment pathways for other diseases. Many pharmaceutical and biotech companies have redirected R&D efforts toward COVID-19 therapies, creating short-term challenges for the plasma fractionation sector.
Strategic Insights for Market Growth
To succeed in the evolving European plasma fractionation market, stakeholders must leverage data-driven insights to navigate industry trends, competitive dynamics, and regional variations. Key strategic considerations include:
- Identifying Untapped Opportunities: Analyzing underserved therapeutic areas or geographic markets to gain a competitive edge.
- Adapting to Local Needs: Tailoring products and services to meet region-specific regulatory, economic, and consumer demands.
- Future-Proofing Business Models: Anticipating long-term market shifts, such as increasing demand for immunoglobulins or advancements in plasma-derived therapies.
By adopting a proactive and localized approach, businesses can optimize resource allocation, refine marketing strategies, and strengthen their market position.
Regional Market Focus
Europe Plasma Fractionation Market varies significantly across countries due to differences in healthcare policies, economic conditions, and patient needs. A deep understanding of these regional nuances is critical for success. Companies should:
- Assess local regulatory frameworks and reimbursement policies.
- Monitor emerging trends, such as the growing preference for specialized plasma products.
- Target high-growth regions while adapting offerings to align with local demand.
A well-defined regional strategy enables companies to maximize market penetration, outperform competitors, and drive sustainable growth in dynamic Europe Plasma Fractionation Market.
Europe Plasma Fractionation Market Segmentation
Europe Plasma Fractionation Market -By Product
- Immunoglobulin
- Intravenous Immunoglobulin (IVIG)
- Subcutaneous Immunoglobulin (SCIG)
- Albumin
- Coagulation Factor Concentrates
- Protease Inhibitors
- Other
Europe Plasma Fractionation Market – BybApplication
- Neurology
- Immunology
- Hematology
- Critical Care
- Pulmonology
- Others
Europe Plasma Fractionation Market – By End User
- Hospitals and Clinics
- Clinical Research Laboratories
- Academic Institutes
Europe Plasma Fractionation Market – By Country
- France
- Germany
- Italy
- Spain
- UK
- Rest of Europe
Europe Plasma Fractionation Market – Company Profiles
- Bharat Serums and Vaccines Limited (BSV)
- Bio Products Laboratory Ltd.
- Biotest AG.
- CSL Limited
- Grifols, S.A.
- Kedrion S.p.A
- Octapharma AG
- Sanquin
- SK Plasma
Other Reports:
North America Medical Marijuana Market: https://business-news-insights.blogspot.com/2025/05/north-america-medical-marijuana-market.html
North America Wound Care Market: https://sites.google.com/view/wound-care-market-n/home
North America Time-of-Flight Sensor Market: https://penzu.com/p/f65bbaf2c60df453
North America Small Satellite Market: https://github.com/SuryakantGadekar/Business-Market-Insights/issues/36
About Us:
Business Market Insights is a market research platform that provides subscription service for industry and company reports. Our research team has extensive professional expertise in domains such as Electronics & Semiconductor; Aerospace & Defense; Automotive & Transportation; Energy & Power; Healthcare; Manufacturing & Construction; Food & Beverages; Chemicals & Materials; and Technology, Media, & Telecommunications.
Author’s Bio:
Suryakant Gadekar
Senior Market Research Expert at Business Market Insights
